Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 01 Feb 2023 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to fourth quarter 2022 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Dec 2022 08:58 CET |
BERGENBIO | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Dec 2022 07:00 CET |
BERGENBIO | BerGenBio to present at DNB's Nordic Healthcare Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Nov 2022 21:30 CET |
BERGENBIO | BerGenBio ASA: Grant of share options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Nov 2022 07:00 CET |
BERGENBIO | BerGenBio reports third quarter 2022 financial results and provides business update | 20103010 Biotechnology | Inside information |
| 08 Nov 2022 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to third quarter 2022 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2022 07:00 CEST |
BERGENBIO | BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS | 20103010 Biotechnology | Inside information |
| 11 Oct 2022 07:00 CEST |
BERGENBIO | BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Sep 2022 15:02 CEST |
BERGENBIO | BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Sep 2022 07:00 CEST |
BERGENBIO | BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Aug 2022 07:00 CEST |
BERGENBIO | BerGenBio reports second quarter and half year 2022 financial results and provides business update | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 09 Aug 2022 07:00 CEST |
BERGENBIO | BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Jun 2022 12:58 CEST |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 06 Jun 2022 18:18 CEST |
BERGENBIO | BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 May 2022 07:00 CEST |
BERGENBIO | BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 May 2022 07:00 CEST |
BERGENBIO | BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 May 2022 07:00 CEST |
BERGENBIO | BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 May 2022 07:00 CEST |
BERGENBIO | BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19 | 20103010 Biotechnology | Inside information |
| 28 Apr 2022 11:28 CEST |
BERGENBIO | BerGenBio ASA: Minutes from the Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Apr 2022 10:51 CEST |
BERGENBIO | BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Apr 2022 07:00 CEST |
BERGENBIO | BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET | 20103010 Biotechnology | Inside information |
| 25 Apr 2022 07:00 CEST |
BERGENBIO | BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Apr 2022 07:00 CEST |
BERGENBIO | BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Apr 2022 15:00 CEST |
BERGENBIO | BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Apr 2022 14:01 CEST |
BERGENBIO | BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021 | 20103010 Biotechnology | Annual financial and audit Reports |
| 17 Mar 2022 08:15 CET |
BERGENBIO | BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Mar 2022 08:00 CET |
BERGENBIO | BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR | 20103010 Biotechnology | Non-regulatory press releases |
| 17 Mar 2022 07:00 CET |
BERGENBIO | BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Feb 2022 12:00 CET |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
| 16 Feb 2022 17:10 CET |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Kapital- og stemmerettsendringer |
| 16 Feb 2022 07:00 CET |
BERGENBIO | BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021 | 20103010 Biotechnology | Inside information |
| 08 Feb 2022 07:00 CET |
BERGENBIO | BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Feb 2022 14:07 CET |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 27 Jan 2022 20:56 CET |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Jan 2022 07:00 CET |
BERGENBIO | BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients | 20103010 Biotechnology | Inside information |
| 10 Jan 2022 19:52 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jan 2022 17:51 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jan 2022 09:04 CET |
BERGENBIO | BERGENBIO - Mandatory notification of trade by Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 06 Jan 2022 10:30 CET |
BERGENBIO | BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Jan 2022 10:27 CET |
BERGENBIO | BerGenBio ASA: Extraordinary General Meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Jan 2022 08:58 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 17 Dec 2021 13:43 CET |
BERGENBIO | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Dec 2021 15:00 CET |
BERGENBIO | BerGenBio ASA: Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Dec 2021 07:30 CET |
BERGENBIO | BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2021 07:43 CET |
BERGENBIO | BerGenBio to present at DNB Nordic Healthcare Conference 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Dec 2021 15:00 CET |
BERGENBIO | BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Nov 2021 17:51 CET |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
| 16 Nov 2021 07:00 CET |
BERGENBIO | BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Nov 2021 16:29 CET |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Total number of voting rights and capital |
| 09 Nov 2021 14:05 CET |
BERGENBIO | BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC) | 20103010 Biotechnology | Inside information |